NYSE:ALC Alcon - ALC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alcon Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $65.40 -1.38 (-2.07%) (As of 03/17/2023 08:53 PM ET) Add Compare Share Share Today's Range$65.30▼$66.0650-Day Range$64.46▼$77.2352-Week Range$55.21▼$81.97Volume1.06 million shsAverage Volume885,908 shsMarket Capitalization$32.05 billionP/E Ratio97.61Dividend YieldN/APrice Target$79.80 ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInstitutional OwnershipHeadlinesShort InterestSocial Media Alcon MarketRank™ ForecastAnalyst RatingHold2.44 Rating ScoreUpside/Downside22.0% Upside$79.80 Price TargetShort InterestHealthy1.16% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth15.83%From $2.59 to $3.00 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector188th out of 983 stocksOphthalmic Goods Industry4th out of 7 stocks 3.2 Analyst's Opinion Consensus RatingAlcon has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $79.80, Alcon has a forecasted upside of 22.0% from its current price of $65.40.Amount of Analyst CoverageAlcon has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.16% of the float of Alcon has been sold short.Short Interest Ratio / Days to CoverAlcon has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Alcon has recently decreased by 5.92%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlcon does not currently pay a dividend.Dividend GrowthAlcon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALC. Previous Next 1.7 News and Social Media Coverage News SentimentAlcon has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.Search InterestOnly 5 people have searched for ALC on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat Follows3 people have added Alcon to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alcon insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.52% of the stock of Alcon is held by insiders.Percentage Held by Institutions43.99% of the stock of Alcon is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Alcon are expected to grow by 15.83% in the coming year, from $2.59 to $3.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alcon is 97.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 119.25.Price to Earnings Ratio vs. SectorThe P/E ratio of Alcon is 97.61, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 95.93.Price to Earnings Growth RatioAlcon has a PEG Ratio of 1.72. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAlcon has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alcon (NYSE:ALC) StockAlcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.Read More Receive ALC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alcon and its competitors with MarketBeat's FREE daily newsletter. Email Address ALC Stock News HeadlinesMarch 12, 2023 | marketwatch.comMedical Supplies Market Continues Aggressive Growth till 2028March 12, 2023 | marketwatch.com2023-2027 Ophthalmic Drugs Market Trends and Advancements: Latest Business Size, Demand, and InnovationsMarch 20, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 10, 2023 | msn.comAlcon's Debt OverviewMarch 10, 2023 | marketwatch.comDry Eye Relief Eye Drops Market Application, Product, Sales and Forecast 2023-2028March 9, 2023 | marketwatch.comGlobal "Intraocular Lens (IOL) Material Market" Size Projection and Analysis for 2023-2028 | Latest Research ReportMarch 7, 2023 | marketwatch.comAngiogenesis Modulators Market Size Regional Analysis 2023 which includes Rapid Growth Rate Till 2025March 1, 2023 | finance.yahoo.comAlcon to Debut TOTAL30 for Astigmatism, Dry Eye and Ocular Health Innovations at SECO 2023March 20, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!February 13, 2023 | finance.yahoo.comAlcon to pay Johnson & Johnson $199 mln to settle eye-laser casesFebruary 13, 2023 | finance.yahoo.comAlcon to pay Johnson & Johnson $199 million to settle eye-laser casesFebruary 2, 2023 | finance.yahoo.comAlcon Canada launches new TOTAL toric lenses for astigmatic patientsJanuary 24, 2023 | marketwatch.comRGP Contact Lenses Market Detailed Analysis of Current Scenario with Growth Forecasts to 2029January 24, 2023 | marketwatch.comSilicon Hydrogel Market 2023 to 2029 by Key Players CIBAVision, Johnson and Johnson, Alcon, CooperVisionJanuary 24, 2023 | finance.yahoo.comAlcon Inc.: Raising target to $85January 14, 2023 | finance.yahoo.comWe Like These Underlying Return On Capital Trends At Alcon (VTX:ALC)January 6, 2023 | finance.yahoo.comAlcon (ALC) Gains From Innovation, Faces FX ChallengesJanuary 5, 2023 | finance.yahoo.comAlcon Introduces a Premium, Reusable Toric Lens with Launch of TOTAL30 for AstigmatismDecember 30, 2022 | finance.yahoo.comWith 57% ownership of the shares, Alcon Inc. (VTX:ALC) is heavily dominated by institutional ownersDecember 28, 2022 | finance.yahoo.comAlcon to Present at 2023 Annual J.P. Morgan Healthcare ConferenceDecember 27, 2022 | nz.finance.yahoo.comGlobal Retinal Laser Equipment Market to Reach $931.7 Million by 2027December 25, 2022 | msn.com7 best canceled TV shows of 2022 that are 90% or higher on Rotten TomatoesDecember 16, 2022 | finance.yahoo.comAlcon (VTX:ALC) investors are sitting on a loss of 18% if they invested a year agoDecember 11, 2022 | marketwatch.comParathyroid Disorders Market 2023 : Company Profile Analysis, Industry Segmentation, Opportunity Assessment and Forecast by 2028December 11, 2022 | marketwatch.comOphthalmic Femtosecond Lasers Market Research on Present State and Future Growth Prospects of Key Players, Forecast by 2023 To 2028December 2, 2022 | finance.yahoo.comWhy Investors Shouldn't Be Surprised By Alcon Inc.'s (VTX:ALC) P/ENovember 30, 2022 | finance.yahoo.comAlcon Prices US$1.3 Billion Senior Notes OfferingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alcon and its competitors with MarketBeat's FREE daily newsletter. Email Address ALC Company Calendar Last Earnings2/27/2023Today3/20/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Ophthalmic goods Sub-IndustryHealth Care Facilities SectorMedical Current SymbolNYSE:ALC CUSIP04544X30 CIK929994 Webwww.alcon.com Phone418172930450Fax41-58-911-3222Employees25,000Year Founded1945Price Target and Rating Average Stock Price Forecast$79.80 High Stock Price Forecast$92.00 Low Stock Price Forecast$68.80 Forecasted Upside/Downside+22.0%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.67 Trailing P/E Ratio97.61 Forward P/E Ratio25.25 P/E Growth1.72Net Income$335 million Net Margins3.84% Pretax Margin5.31% Return on Equity5.66% Return on Assets3.94% Debt Debt-to-Equity Ratio0.23 Current Ratio1.87 Quick Ratio1.11 Sales & Book Value Annual Sales$8.72 billion Price / Sales3.68 Cash Flow$4.43 per share Price / Cash Flow14.75 Book Value$40.15 per share Price / Book1.63Miscellaneous Outstanding Shares490,090,000Free Float482,638,000Market Cap$32.05 billion OptionableNot Optionable Beta0.89 Social Links Key ExecutivesDavid J. EndicottChief Executive Officer & DirectorTimothy C. StonesiferChief Financial Officer & Senior Vice PresidentEdward McGoughHead-Global Manufacturing & Technical OperationsFranck LeveillerSVP, Head-Global Research & DevelopmentSue-Jean LinSVP, Chief Information & Transformation OfficerKey CompetitorsCooper CompaniesNYSE:COOBioNTechNASDAQ:BNTXResMedNYSE:RMDAmerisourceBergenNYSE:ABCCenteneNYSE:CNCView All CompetitorsInstitutional OwnershipB. Riley Wealth Advisors Inc.Sold 315 shares on 3/15/2023Ownership: 0.002%Nordwand Advisors LLCBought 6,905 shares on 3/7/2023Ownership: 0.001%Rockefeller Capital Management L.P.Bought 6,701 shares on 3/6/2023Ownership: 0.007%Voya Investment Management LLCBought 182,855 shares on 2/28/2023Ownership: 0.157%Northwestern Mutual Wealth Management Co.Bought 171 shares on 2/21/2023Ownership: 0.001%View All Institutional Transactions ALC Stock - Frequently Asked Questions Should I buy or sell Alcon stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alcon in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ALC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALC, but not buy additional shares or sell existing shares. View ALC analyst ratings or view top-rated stocks. What is Alcon's stock price forecast for 2023? 9 equities research analysts have issued twelve-month price objectives for Alcon's stock. Their ALC share price forecasts range from $68.80 to $92.00. On average, they anticipate the company's stock price to reach $79.80 in the next year. This suggests a possible upside of 22.0% from the stock's current price. View analysts price targets for ALC or view top-rated stocks among Wall Street analysts. How have ALC shares performed in 2023? Alcon's stock was trading at $68.55 on January 1st, 2023. Since then, ALC stock has decreased by 4.6% and is now trading at $65.40. View the best growth stocks for 2023 here. Are investors shorting Alcon? Alcon saw a drop in short interest during the month of February. As of February 28th, there was short interest totaling 5,720,000 shares, a drop of 5.9% from the February 13th total of 6,080,000 shares. Based on an average daily trading volume, of 846,700 shares, the days-to-cover ratio is currently 6.8 days. Currently, 1.2% of the shares of the stock are short sold. View Alcon's Short Interest. When is Alcon's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our ALC earnings forecast. How were Alcon's earnings last quarter? Alcon Inc. (NYSE:ALC) released its earnings results on Monday, February, 27th. The healthcare company reported $0.42 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.42. The healthcare company earned $2.17 billion during the quarter, compared to analysts' expectations of $2.14 billion. Alcon had a net margin of 3.84% and a trailing twelve-month return on equity of 5.66%. How often does Alcon pay dividends? What is the dividend yield for Alcon? Alcon announced a dividend on Saturday, April 23rd. Investors of record on Monday, May 2nd will be paid a dividend of $0.13 per share on Tuesday, May 3rd. This represents a yield of 0.18%. The ex-dividend date is Friday, April 29th. Read our dividend analysis for ALC. What guidance has Alcon issued on next quarter's earnings? Alcon updated its FY23 earnings guidance on Tuesday, February, 28th. The company provided EPS guidance of $2.55-2.65 for the period, compared to the consensus earnings per share estimate of $2.54. The company issued revenue guidance of $9.2-9.4 billion, compared to the consensus revenue estimate of $9.26 billion. What is Greg D. Wight's approval rating as Alcon's CEO? 6 employees have rated Alcon Chief Executive Officer Greg D. Wight on Glassdoor.com. Greg D. Wight has an approval rating of 100% among the company's employees. This puts Greg D. Wight in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alcon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alcon investors own include AT&T (T), Novartis (NVS), Verizon Communications (VZ), International Business Machines (IBM), Intel (INTC), Pfizer (PFE), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Exxon Mobil (XOM) and AbbVie (ABBV). What is Alcon's stock symbol? Alcon trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALC." Who are Alcon's major shareholders? Alcon's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Credit Suisse AG (2.68%), Norges Bank (2.39%), Clearbridge Investments LLC (2.09%), Zurcher Kantonalbank Zurich Cantonalbank (1.49%), T. Rowe Price Investment Management Inc. (1.30%) and Brown Brothers Harriman & Co. (1.15%). How do I buy shares of Alcon? Shares of ALC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alcon's stock price today? One share of ALC stock can currently be purchased for approximately $65.40. How much money does Alcon make? Alcon (NYSE:ALC) has a market capitalization of $32.05 billion and generates $8.72 billion in revenue each year. The healthcare company earns $335 million in net income (profit) each year or $0.67 on an earnings per share basis. How many employees does Alcon have? The company employs 25,000 workers across the globe. Does Alcon have any subsidiaries? The following companies are subsidiares of Alcon: Alcon (China) Ophthalmic Product Co. Ltd., Alcon Finance Corporation, Alcon Japan Ltd., Alcon Laboratories Inc., Alcon Pharmaceuticals Ltd., Alcon Research LLC, and Alcon Vision LLC.Read More How can I contact Alcon? Alcon's mailing address is Rue Louis-d`Affry 6, Fribourg V8, 1701. The official website for the company is www.alcon.com. The healthcare company can be reached via phone at 418172930450, via email at investor.relations@alcon.com, or via fax at 41-58-911-3222. This page (NYSE:ALC) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.